/
BLRX
$3.10-$0.06 (-2.05%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$13.8M
4M shares
52-week range
$2.15 – $5.06
33% from low
Exchange
NASDAQ
ADRC
Borrow rate
45.10%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-112.90
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $4.8M | $28.9M | $1.2M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $3.7M | $9.3M | $759.0K |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $1.1M | $19.7M | $430.4K |
| Gross margin | — | — | — | — | — | 23.1% | 68.0% | 36.2% |
| R&D | $19.8M | $23.4M | $18.2M | $19.5M | $17.6M | $12.5M | $9.1M | $7.7M |
| Operating income | −$25.6M | −$28.1M | −$22.9M | −$24.8M | −$29.2M | −$49.7M | −$20.4M | −$10.4M |
| EBITDA | −$22.0M | −$22.7M | −$27.6M | −$25.4M | −$22.1M | −$57.1M | $3.9M | −$224.8K |
| Net income | −$23.0M | −$25.4M | −$30.0M | −$27.1M | −$25.0M | −$60.6M | −$9.2M | −$1.2M |
| Net margin | — | — | — | — | — | -1262.8% | -31.9% | -99.6% |
| EPS (diluted) | -3.15 | -2.70 | -1.80 | -0.61 | -0.48 | -0.94 | -0.12 | -0.29 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-0.47 | $-0.48–$-0.45 | 1 |
| 2027 | $2M | $-0.32 | $-0.33–$-0.31 | 1 |
| 2028 | $6M | $-0.33 | $-0.34–$-0.31 | 1 |
| 2029 | $7M | $-0.60 | $-0.62–$-0.58 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.50
Price
$3.10
Implied downside
-84%
Peer comparison
BioLineRX Ltd
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
www.biolinerx.com- Employees
- 24
- IPO / List date
- Jul 25, 2011
Held by traders on TradeandTell
No one on the platform currently holds BLRX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in BLRX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-01-30 | 1-for-40reverse |
| 2019-07-15 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded BLRX yet.
